Treatment of T-Large Granular Lymphocyte (T-LGL) Lymphoproliferative Disorders With Alemtuzumab (Campath)

Trial Profile

Treatment of T-Large Granular Lymphocyte (T-LGL) Lymphoproliferative Disorders With Alemtuzumab (Campath)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Oct 2017

At a glance

  • Drugs Alemtuzumab (Primary)
  • Indications T cell prolymphocytic leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Oct 2017 Status changed from recruiting to active, no longer recruiting.
    • 13 Oct 2017 Status changed from recruiting to active, no longer recruiting.
    • 17 Nov 2015 Planned End Date changed from 1 Dec 2016 to 1 Dec 2019 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top